# 泰福生技國際級 CDMO 戰隊首度亮相 Bio Asia – Taiwan
# 以「Bora Biologics」打響唯一在美擁有廠區產能之台灣生物製劑品牌
# Bora Biologics Makes Its Debut at Bio Asia–Taiwan 2025
# The Only Taiwan-Based Biologics CDMO with Commercial-Scale Manufacturing Capability in the U.S.

**台北，台灣，2025 年 7 月 25 日**－泰福生技股份有限公司（以下簡稱「泰福生技」，台灣證券交易所股票代碼：6541）自今年 1 月與保瑞集團完成策略聯盟後、本周正式以旗下 CDMO 業務品牌「Bora Biologics」參加 2025 Bio Asia – Taiwan 亞洲生技大會，這是公司在 CDMO 業務品牌整合後首度參展，由執行長 Steve Lam 親自領軍、率領商務長 Marc Goemans 及全球業務發展團隊，並與策略聯盟夥伴保瑞集團強強聯手，展現推動全球大分子 CDMO 業務的企圖心與實力。

Taipei, Taiwan – July 25, 2025 – Tanvex BioPharma Inc. (TWSE: 6541), currently operating its CDMO business under the brand **Bora Biologics** following the strategic alliance with Bora Group in January this year, is proud to make its official debut at **Bio Asia–Taiwan 2025**. This marks the company's first major, joint-force public showcase under the refreshed CDMO brand. The delegation is led by CEO Stephen Lam, joined by Chief Commercial Officer Marc Goemans and the global business development team. Together with strategic partner Bora Group, Bora Biologics presents its growing capabilities and bold ambitionin global biologics CDMO services.

面對全球產業及國家政策快速變遷的競爭環境，泰福生技不僅持續在全球最大醫藥市場美國針對客戶需求擴建商業量產廠區、旗下聖地牙哥廠 2000 升產能擴建計畫正如火如荼進行中，預計將於 2026 年第一季正式啟用；更於日前與國際大廠 Cipla 正式簽約，攜手推動泰福生技首項生物相似藥 NYPOZI™（原廠參考藥物為白血球增生劑 Neupogen®）正式進軍美國市場。這項泰福生技首個在美國市場上市銷售的生物製劑產品將使得聖地牙哥廠區正式成為具有商業化量產實績的生產據點，大幅提升泰福生技贏得美國在地客戶後期商業量產訂單之競爭優勢。而此一交易也代表著 Cipla 正式成為泰福生技聖地牙哥廠區的第一個 CDMO 商業量產客戶，未來泰福生技內部資源可心無旁騖地聚焦 CDMO 業務發展！

In response to the rapidly shifting global industry landscape and policy environment, Bora Biologics continues to expand its commercial-scale manufacturing footprint in the world's largest pharmaceutical market, the United States. The company's San Diego Site is undergoing a major 2,000L capacity expansion project, scheduled for completion in Q1 2026. In addition, Bora Biologics recently signed a commercial supply agreement with leading global pharmaceutical company Cipla to launch its first biosimilar product, **NYPOZI™** (reference product: Neupogen®), in the U.S. market. This milestone marks Bora Biologics' first commercial launch in the U.S. and establishes its San Diego Site as a proven commercial manufacturing facility. The deal is expected to significantly enhance the company's

competitiveness in winning future late-stage and commercial production contracts from U.S.-facing clients. With this transaction, Cipla also becomes the San Diego Site's first commercial stage CDMO client. Meanwhile, Bora Biologics team may fully pivot its internal resources toward CDMO business growth.

此外，泰福生技在竹北廠區的前期開發團隊亦同步強化升級自有技術，旗下抗體藥物複合體 ADC 實驗室全新落成，具備生物偶聯 bioconjugation 關鍵技術所必須之人才、設備與技術。其中，擴建後之竹北廠區包含設有 isolator 系統之製程開發實驗室，能夠進行毒理批次生產、即動物實驗用藥等級之 ADC 產品，同步支援三大主流技術，包括 Cys-based、Lys-based 與 Site Specific-based 等不同偶聯技術，並已建立完整且自主之 ADC 分析平台。此一技術平台已獲客戶青睞肯定，目前正在執行之 ADC 專案預計將於 2026 年第一季完成 500 升之 GMP 生產批，預計將可再創業務開發另一新里程碑。

On top of these positive development, Bora Biologics has also expanded its Zhubei Site in Taiwan, reinforcing its early-phase development capabilities. The company has completed a state-of-the-art **Antibody-Drug Conjugate (ADC) laboratory**, equipped with specialized infrastructure, skilled talent, and key technologies for advanced bioconjugation development.

The newly expanded ADC platform includes:

- A process development lab with isolator technology, capable of producing toxicology-grade ADC materials for preclinical studies
- Support for cysteine-based, lysine-based, and site-specific conjugation methods
- A fully integrated, in-house ADC analytical platform

These capabilities have already been validated by client demand. An ongoing ADC project is scheduled to complete a 500L GMP batch in Q1 2026, representing another major milestone in business development.

今年除了與會參展外，泰福生技亦於本次議程中主持了一場策略論壇，主題為：「Decision Making on Outsourcing in the Current Changing Economic Environment（變動經濟環境下的委外開發決策）」，邀請國內外領導創新公司聖安生醫與 Aridis Pharmaceuticals 共同參與，探討在近期創新生物醫藥公司在挑選 CDMO 合作夥伴時的決策考量與關鍵因素。

Beyond its presence on the exhibition floor, Bora Biologics also **hosted the innovation forum panel** forum during Bio Asia conference, titled: **"Decision Making on Outsourcing in the Current Changing Economic Environment."** The panel featured leading innovators **St. Shine Biomedical** and **Aridis Pharmaceuticals**, who joined Bora Biologics in a discussion on the evolving criteria biotech companies use to evaluate CDMO partners.

與會來賓指出，雖著產業競爭加劇且更為多元化，委外決策已不再僅以「成本」為唯一考量，反而更為重視前期開發的 Time Discipline （準時交付）、以及後期量產之

Expertise（技術專長與實績）與 Quality & Compliance（品質合規），以確保投資效率及 Time-to-market 的市場先進優勢。過去兩年中，泰福生技的竹北廠區已完成超過 35 個 CDMO 客戶服務、且準時交付（On-Time Devlivery）比例達 100%，這項實績將賦予合併後的「Bora Biologics」品牌平台為全球客戶提供更加靈活、更為全面的一站式（end-to-end）解決方案。此外，做為唯一在美國本土擁有產能之台灣生物製劑公司，泰福已領先市場做好萬全準備，將能為全球生物醫藥客戶創造品質、時間與成本的三重效益。

Panelists observed that as competition intensifies and diversifies, outsourcing decisions are no longer based solely on cost. Increasingly, clients prioritize three key dimensions: Timeline Discipline in early-stage development, Expertise in commercial production and regulatory success, and Quality & Compliance when talking about speed-to-market. Over the past two years, Bora Biologics' Zhubei Site has delivered over 35 CDMO projects, achieving a 100% on-time delivery, a track record that reinforces the brand's integrated, end-to-end capabilities. As the only Taiwan-based biologics CDMO with commercial-scale manufacturing capacity in the United States, Bora Biologics is uniquely positioned to deliver a rare combination of quality, speed, and cost-effectiveness to global biopharma partners at its vicinity.

**關於泰福生技**

泰福生技股份有限公司（台灣證券交易所：6541）成立於2011年，其使命是通過使生物製劑更加經濟實惠且提高可取得性來革新全球醫藥產業。多年來，泰福生技在生物製劑開發和製造方面不斷精進專業知識，最終成功實現了第一個產品的商業化。隨著另一個生物製劑許可申請（BLA）正等待美國FDA批准，泰福生技的發展歷程體現了對卓越、創新的堅定承諾，以及改善患者醫藥服務的熱忱。泰福生技致力於推進醫療保健，這促使其以「Bora Biologics」的品牌擴展了作為CDMO的能力。整併前的保瑞生技已擁有超過70批成功的cGMP製造記錄，為全球生物製藥公司提供靈活、全面的一站式服務方案，在確保品質的同時、提高時間和成本效率。通過利用其全球CDMO能力、美國FDA核准通過的先進設施，以及在生物製劑開發和製造方面的深厚專業知識，保瑞生技為其客戶確保了高效且有效的市場進入途徑。

**【新聞聯絡人】**

泰福生技 欒君儀 Angela Luan: angela.luan@tanvex.com 0922-407094